GW870086 0.2%

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Dermatitis, Atopic

Phase 1

A Study Assessing GW870086's Potential to Cause Skin Thinning

CompletedNCT01381445

GlaxoSmithKlineDermatitis, Atopic

Start: 2011-04-14End: 2011-07-07Updated: 2017-07-21

Phase 2

A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo

CompletedNCT01299610

GlaxoSmithKlineDermatitis, Atopic

Start: 2010-12-01End: 2011-04-14Updated: 2017-11-17